A SPAC III Acquisition Corp. Reports Q3 2025 Net Income Turnaround and Merger Plans with Bioserica International

A SPAC III Acquisition Corp. reported its financial results for the third quarter ending September 30, 2025, revealing a net income of $480,352, a significant turnaround from a net loss of $38,778 in the same period last year. For the nine months ended September 30, 2025, the company recorded a net income of $1,273,493, compared to a loss of $46,778 in the prior year. The increase in profitability is attributed to interest income of $654,307 for the quarter and $1,948,362 for the nine-month period, which contrasts sharply with the absence of such income in the previous year.

The company’s total assets as of September 30, 2025, amounted to $63,360,882, up from $62,075,158 at the end of 2024. This increase was primarily driven by a rise in investments held in the trust account, which grew to $62,268,671 from $60,356,959. However, total liabilities remained relatively stable, with current liabilities slightly increasing to $529,565 from $517,334. The company’s cash position decreased to $1,062,632 from $1,598,890, reflecting ongoing operational expenses.

In terms of strategic developments, A SPAC III Acquisition Corp. is in the process of merging with Bioserica International Limited, a company focused on bio-based antimicrobial materials. The merger agreement, signed on May 23, 2025, outlines an aggregate consideration of $217,860,000, which includes the issuance of 20 million Class B ordinary shares and 1.786 million Class A ordinary shares. This merger is part of the company’s strategy to complete its initial business combination, which has been extended to November 12, 2026, following shareholder approval on October 27, 2025.

Operationally, the company has not yet commenced any revenue-generating activities, as it remains focused on identifying and evaluating potential business combinations. As of the latest report, the company had 837,581 Class A ordinary shares and 1,500,000 Class B ordinary shares outstanding. The company’s management has indicated that it may need to secure additional financing to meet its obligations or to complete its business combination, highlighting the ongoing uncertainty regarding its future operations.

Looking ahead, A SPAC III Acquisition Corp. aims to leverage its current financial position and strategic partnerships to successfully execute its merger with Bioserica and fulfill its business objectives. However, the company acknowledges the risks associated with market conditions and the potential need for further financing, which could impact its ability to continue as a going concern if the business combination is not completed within the extended timeframe.